Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1409556

Dupilumab: A promising treatment option for adult linear IgA bullous dermatosis with severe pruritus

Provisionally accepted
Li Wang Li Wang 1Jing Peng Jing Peng 2Jinbo Chen Jinbo Chen 2*
  • 1 Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, Hebei Province, China
  • 2 Department of Dermatology, Wuhan Children’s Hospital, Wuhan, Hubei Province, China

The final, formatted version of the article will be published soon.

    Linear IgA bullous dermatosis (LABD) is an acquired autoimmune subepidermal blistering disorder. Diagnosis always relies on skin pathology and direct immunofluorescence (DIF), with typical linear deposits of IgA along the basement membrane zone (BMZ). The typical clinical manifestation is tense bullae arranged like the “string of pearls” companied with severe pruritus. Dapsone is often considered first-line therapy for LABD, and it is necessary to test the HLA-B*1301 gene to prevent the occurrence of dapsone-induced hypersensitivity syndrome (DHS). Here we report a case of LABD resistant to corticosteroid and sulfasalazine, while waiting for HLA-B*1301 gene test results, dupilumab was used to control severe pruritus.

    Keywords: Linear IgA bullous dermatosis (LABD), Dupilumab, Pruritus, Dapson, HLA-B*1301

    Received: 30 Mar 2024; Accepted: 17 Jul 2024.

    Copyright: © 2024 Wang, Peng and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jinbo Chen, Department of Dermatology, Wuhan Children’s Hospital, Wuhan, Hubei Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.